Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, is pleased to
announce that SeeThruEquity, LLC ("SeeThruEquity") of New York, NY has initiated
research coverage of COTI. 


The initial research report is dated June 12, 2014 and is available from
SeeThruEquity by contacting them at http://www.seethruequity.com. 


About SeeThruEquity 

SeeThruEquity is a New York, NY based equity research and corporate access firm
focused on companies with less than $1 billion in market capitalization.
SeeThruEquity does not conduct any investment banking or commission based
business and the research reports it prepares are not paid for by the issuers
being reported upon and are unbiased. SeeThruEquity is approved to contribute
its research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks
and distributes its research to its database of opt-in investors. SeeThruEquity
also contributes its estimates to Thomson Estimates, the leading estimates
platform on Wall Street. 


SeeThruEquity was started in March 2011. Since then, the company has initiated
coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of
industries including technology, health care, consumer, energy and special
situations and have hosted several investor conferences in New York City. 


About Critical Outcome Technologies Inc. 

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective. 


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024